Despite the heterogeneity in MS disease course, selecting an appropriate therapy for relapsing forms of MS (RMS) before the approval of fingolimod in 2010 [12, 13] was relatively simple because neurologists had two main treatment options: interferon beta/glatiramer acetate or natalizumab. The gene discussed is IFNB1; the disease is myeloid sarcoma.